Clinical Trials Logo

Clinical Trial Summary

Treatment of hookworm infected groups with albendazole has been shown to result in an increase in hemoglobin levels and a related decrease in the prevalence of anemia. Increases in hemoglobin levels due to treatment have been associated with significant gains in adult labor productivity.

In this study, the investigators hypothesize that regular treatment of women smallholder farmers in a high prevalence area with the anti-hookworm drug albendazole and iron supplementation will improve hookworm associated anemia. Further, regular treatment of albendazole and iron supplementation will improve their work capacity when compared to a control group


Clinical Trial Description

DRC has one of the world's highest prevalences (frequencies) of Soil Transmitted Helminths (STH), a group of intestinal parasites that include Ascaris, Trichuris and hookworm, each of which can have significant impacts on the health and nutritional status of children.(1)(2)(3) In addition, hookworm, because of prevalence increases noted during adulthood in many countries and because of its relationship to significant intestinal blood loss, can also have a significant impact on the health and nutritional status of adults.

Hookworm spreads easily in places without adequate control of feces; hookworm eggs are excreted in feces of infected people, transition to larvae, and usually enter the body through the skin on the bottom of the feet of other people who are not wearing footwear.

Much of hookworm's health impact is mediated through intestinal blood loss as hookworms attach to the human intestinal wall and digest the hemoglobin in human red blood cells. That blood loss leads to - or exacerbates - iron deficiency and eventually to iron deficiency anemia (IDA). Because of menstrual blood losses, the large iron demands of pregnancy, and the often low iron content of their diets, many women of childbearing age are at risk of iron deficiency even without hookworm exposure. Any blood loss associated with hookworm infection would exacerbate a pre-existing iron deficiency.

Iron deficiency with or without anemia has also been associated in several studies with lower aerobic work capacity. IDA can effect an individual's ability to perform economic generating tasks (work output) threaten one's livelihood and possibly food security. The World Health Organization (WHO) estimates an annual loss of 19.7 million disability-adjusted life years (1.3% of the global total) is due to IDA with high burden in Africa (25%), an area which can least afford it. The median annual economic loss due to IDA has been estimated at 4% of gross domestic product in 10 different developing countries.

Albendazole and Mebendazole are anti-helminthic drugs that that can cure or reduce the severity (as measured by stool egg counts) of many hookworm infections. The major programmatic use of these drugs is in programs of school-based mass drug administration (MDA) as recommended treatment strategies have traditionally prioritized school-aged children. Large amounts of these drugs are now being provided without charge by their manufacturers, Merck and Johnson & Johnson respectively, and distributed through W.H.O. and ministries of health to support current goals of control of pediatric hookworm and other STH infections.

Treatment of hookworm infected groups with Albendazole has been shown to result in an increase in hemoglobin levels and a related decrease in the prevalence of anemia. Increases in hemoglobin levels due to treatment have also been associated with significant gains in adult labor productivity as measured in Kenyan road construction workers (16) and in Bangladeshi women plantation tea pickers. However, the cure or amelioration of hookworm infection caused by these drugs is not permanent; re-infection can occur within weeks or months in heavily exposed people. Few studies have measured work productivity beyond 2-3 months and minimal information is available for longer term treatment.

This study is in response to the Bill and Melinda Gates Foundation Grand Challenges Explorations RFP targeted specifically at "Labor Saving Strategies and Innovations for Women Smallholder Farmers." As hookworm in endemic areas is thought to be one of the primary causes of IDA and IDA is known to decrease work productivity, then subsistence farmers will ideally report improved productivity if hookworm is treated. Although the benefits of this proposed intervention are not directly targeted at that specific goal, i.e., are not intended to reduce the amount of necessary labor, the benefits of this intervention could lead indirectly to the same result(s) through an increase of women's ability to accomplish a fixed amount of work.

The Democratic Republic of Congo is thought to be an appropriate location as it has one of the world's highest burdens of NTD disease with an estimated 31 million hookworm cases, second only to Nigeria for disease prevalence in Africa. The population is also particularly vulnerable as moderate to heavy hookworm infections has been associated with lower hemoglobin levels (in both children and adults) and thus with a greater risk of iron deficiency and anemia. DRC has also been identified by USAID as a country in need of urgent NTD disease surveillance and control activities. Information from this study will ideally extend understanding of this disease process and provide information regarding inclusion of anthelmintic treatment in maternal and other public health packages.

Study Purpose The purpose of this study is to determine whether regular treatment of women smallholder farmers with the anti-hookworm drug Albendazole over a one-year period would have an impact on their work capacity and possible productivity as small farmers. The intention is to identify and enroll in an intervention study a group of women smallholder farmers who are not pregnant in their first trimester of pregnancy, are not acutely ill with malaria, and living in areas with poor sanitation and with endemic hookworm. Many of these women would presumably be iron deficient, at least in part due to the blood loss associated with hookworm infection.

Study Aims

1. To determine prevalence of hookworm infection in the Safe Motherhood cohort

2. To determine the prevalence of anemia in the Safe Motherhood cohort

3. To determine the change in Hemoglobin of female subsistence small farmers who have been treated with Albendazole and daily iron supplementation at 6 and 12 months.

4. To determine the change in work tolerance as measured by the STEP test when female subsistence small farmers have been given Albenzazole and iron supplementation at 6 and 12 months ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02102321
Study type Interventional
Source Salmon, Margaret, M.D.
Contact Margaret Salmon, MD MPH
Phone 647 704 5938
Email margiesalmon@gmail.com
Status Recruiting
Phase N/A
Start date March 2014
Completion date August 2015

See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Active, not recruiting NCT02101944 - Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A